Biological & operational considerations for iPSC-derived cell production

Cell & Gene Therapy Insights 2023; 9(11), 1493–1501

DOI: 10.18609/cgti.2023.196

Published: 12 January
Innovator Insight
Austin Mogen

While cell therapies offer great promise, questions remain on the most effective tools and processes for transitioning from the lab bench into the production suite. In this roundtable discussion, four experts discuss considerations and challenges for scale-up of induced pluripotent stem cells. Methods and solutions for scaling production will be discussed, including biological and operational process optimizations.